ArticleRheumatology (Oxford, England)2026
Soluble SIGLEC1 as a biomarker of disease activity in idiopathic inflammatory myopathies.
Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectivesTo investigate soluble circulating sialic acid-binding Ig-like lectin 1 (scSIGLEC1), a surrogate biomarker for type I IFN, as a novel biomarker for idiopathic inflammatory myopathies (IIM) disease activity.
methodsPatients enrolled in a Canadian multicentre cohort of IIM patients with biobanked serum samples and clinical data at baseline and 1-year follow-up were included. Serum scSIGLEC1 levels at baseline were tested using a capture immunoassay and evaluated in relation to disease activity, defined using patients' Physician Global Activity (PGA) scores, Total Improvement Scores (TIS) and visual analogue scale scores for the six organ systems included in the Myositis Disease Activity Assessment Visual Analogue Scales (MYOACT): constitutional, cutaneous, skeletal, gastrointestinal, pulmonary and cardiovascular. Performance of scSIGLEC1, MYOACT and creatine kinase to assess disease activity were compared [area under the receiver operating characteristic curve (ROC AUC)].
resultsA total of 87 IIM patients (67.8% female, mean age 54.4 ± 14.3 years) were included. Higher scSIGLEC1 levels differentiated between active and inactive disease on the PGA (difference 2.7 ng/ml; 95% CI 0.7-4.8). Higher scSIGLEC1 levels were found among patients with cutaneous (difference 1.7 ng/ml; 95% CI 0.1-3.4), skeletal (difference 2.0 ng/ml; 95% CI 0.1-3.9) and gastrointestinal (difference 2.2 ng/ml; 95% CI 0.5-3.9) disease activity compared with patients without disease activity in these extramuscular organs, and were associated with lower TIS scores at 1-year follow-up. scSIGLEC1 levels (ROC AUC 0.74; 95% CI 0.61-0.86) matched MYOACT performance and outperformed creatine kinase in assessing disease activity.
conclusionscSIGLEC1 levels are a promising biomarker for monitoring overall IIM disease activity, as well as activity involving the cutaneous, musculoskeletal and gastrointestinal systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.